This clinical trial is focused on studying the effects of a medication called empagliflozin on patients experiencing cardiogenic shock. Cardiogenic shock is a serious condition where the heart suddenly can’t pump enough blood to meet the body’s needs. The medication being tested, empagliflozin, is a type of drug known as a sodium glucose cotransporter 2 (SGLT2) inhibitor, which is commonly used to treat diabetes. In this study, empagliflozin is being used to see if it can help improve outcomes for patients with cardiogenic shock.

The purpose of the study is to compare the effects of starting empagliflozin early, in addition to the usual treatment, versus the usual treatment alone. The study will last for about three months. During this time, researchers will look at several important health outcomes, such as survival rates, the need for rehospitalization, heart function, and kidney function. Participants will be randomly assigned to receive either empagliflozin along with their usual care or just the usual care without empagliflozin.

Throughout the study, doctors will monitor participants’ heart and kidney health, as well as other factors like weight and liver function. The goal is to see if adding empagliflozin to the treatment plan can improve the overall health and recovery of patients with cardiogenic shock. This research could provide valuable insights into new ways to support patients with this challenging condition.